[Remote] Senior Director, Regional Sales – South Central at Axsome Therapeutics Inc

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Bachelor’s degree required; advanced degree preferred (or equivalent experience)
12+ years of healthcare/biopharmaceutical experience
5+ years of front-line sales management experience
Proven track record in specialty or rare disease sales, with a preference for experience in rare disease where there are multiple medicines an HCP may choose from (nephrology experience a plus)
Consistent history of top sales performance as a leader, recognition/awards, and leadership experience
Experience in building and managing high-performing teams
Strong leadership and coaching skills
Excellent communication and interpersonal skills
Ability to travel extensively within the region (3-4 days/week) and to headquarters in San Francisco and national and regional meetings as required
Experience in cross-functional collaboration and patient support services
Strong business acumen and financial management skills
Experience in driving sales performance and achieving or exceeding targets
Ability to demonstrate expertise in IgAN, its evolving treatment landscape, and the patient journey
Experience in operational excellence and compliance with legal, regulatory, and company policies

Responsibilities

Hire, coach, and inspire a high-performing team of rare disease sales specialists
Create a culture of accountability, resilience, and continuous learning
Serve as a role model for Vera’s values, compliance standards, and commitment to patients
Drive sales performance and achieve or exceed regional targets for new patient starts and/or other appropriate objectives
Act as a player-coach by building strong relationships with key HCPs and accounts
Lead regional execution of launch strategies to bring atacicept to patients with IgAN
Partner with colleagues in Patient Support, Field Reimbursement, Marketing, Regional Marketing, and other customer-facing functions
Provide strategic input to shape regional and national initiatives with a patient-first mindset
Demonstrate expertise in IgAN, its evolving treatment landscape, and the patient journey
Drive success by applying financial and business acumen, including budget oversight and P&L management
Foster a culture that ensures compliance with legal, regulatory, and company policies
Travel extensively within the region (3-4 days/week) and to headquarters in San Francisco and national and regional meetings as required
Participate in territory meetings and training sessions
Collaborate with cross-functional teams to achieve business objectives

Skills

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free